Hydrogen sulfide (H₂S) donors represent an emerging therapeutic approach for Parkinson's Disease that leverages the endogenous gasotransmitter's potent antioxidant, anti-inflammatory, and mitochondrial protective properties. While a general page on H₂S-releasing compounds exists, it lacks dedicated Parkinson's Disease therapeutic content despite growing preclinical evidence supporting H₂S-based interventions for dopaminergic neuroprotection.
H₂S is produced endogenously in the brain through three primary enzymatic pathways:
- Cystathionine β-synthase (CBS): Primarily expressed in astrocytes, highly sensitive to vitamin B6 status
- Cystathionine γ-lyase (CSE): Predominantly in endothelial cells and neurons
- 3-mercaptopyruvate sulfurtransferase (3-MST): Mitochondria-based production, particularly in neurons
These enzymes convert cysteine to H₂S, which acts as a gaseous signaling molecule at nanomolar to micromolar concentrations.
Multiple lines of evidence demonstrate H₂S system impairment in Parkinson's Disease:
- CBS deficiency: Post-mortem studies show reduced CBS expression in substantia nigra of PD patients
- Impaired H₂S signaling: Decreased H₂S bioavailability in plasma and CSF of PD patients
- Correlation with severity: Lower H₂S levels correlate with more severe motor symptoms
- Genetic links: CBS polymorphisms associated with increased PD risk
flowchart TD
A["H₂S Donors"] --> B["Mitochondrial Protection"]
A --> C["Antioxidant Effects"]
A --> D["Anti-inflammatory"]
A --> E["Anti-apoptotic"]
B --> B1["Complex IV inhibition"]
B --> B2["ATP restoration"]
B --> B3["mtROS reduction"]
C --> C1["Nrf2 activation"]
C --> C2["SOD upregulation"]
C --> C3["GSH restoration"]
D --> D1["NF-κB inhibition"]
D --> D2["TNF-α reduction"]
D --> D3["Microglial deactivation"]
E --> E1["Bcl-2 upregulation"]
E --> E2["Caspase inhibition"]
E --> E3["PARP inhibition"]
F["Dopaminergic Neuron Survival"] --> G["Motor Function Preservation"]
GYY4137 is a slow-releasing H₂S donor that provides sustained, physiological H₂S concentrations:
- Structure: Morpholin-4-yl 1-morpholoinephosphonothioate
- Release kinetics: Time-dependent release over hours (not burst)
- Key studies:
- Attenuates 6-OHDA-induced rotational behavior in rats
- Protects SH-SY5Y cells from rotenone toxicity
- Improves mitochondrial membrane potential in patient-derived iPSC neurons
- Dosing: 50-100 mg/kg in preclinical models
AP39 is a mitochondria-targeted H₂S donor (mitoClick):
- Mechanism: Accumulates in mitochondria via triphenylphosphonium moiety
- Key studies:
- Protects against MPTP-induced dopaminergic loss
- Reduces mitochondrial superoxide in primary neurons
- Improves complex I activity in PD models
- Advantage: Direct mitochondrial delivery at lower doses
- Mechanism: Fast-releasing H₂S donor (instant release)
- Key studies:
- Reduces LPS-induced neuroinflammation in rat model
- Improves motor function in 6-OHDA model
- Limitation: Rapid H₂S release can cause cytotoxicity at high doses
- Status: Human clinical trials for cardiovascular disease (completed)
- Potential: First-in-class H₂S donor advancing toward neurological indications
- Advantage: Clinically validated safety profile
| Compound |
Model |
Outcome |
Reference |
| GYY4137 |
6-OHDA rats |
↓ Rotational behavior, ↓ TH loss |
|
| GYY4137 |
MPTP mice |
↓ Motor deficits, ↓ α-syn aggregation |
|
| AP39 |
MPTP mice |
↓ Dopaminergic loss, ↓ ROS |
|
| NaHS |
LPS rats |
↓ TNF-α, ↓ IL-1β, improved gait |
|
| GYY4137 |
iPSC neurons |
↑ ATP, ↑ mitochondrial respiration |
|
- Current stage: Preclinical to early Phase I transition
- Challenges:
- BBB penetration of H₂S donors
- Optimal dosing for CNS delivery
- Sustained vs. pulsatile H₂S release
- Opportunities: Combination with L-DOPA or CoQ10
gantt
title H₂S Donor Development for PD
dateFormat YYYY
section Discovery
Compound optimization :done, des1, 2020, 2022
Lead identification :done, des2, 2022, 2024
section Preclinical
In vitro efficacy :active, pre1, 2023, 2025
In vivo PD models :active, pre2, 2024, 2026
IND-enabling studies :pre3, 2025, 2027
section Clinical
Phase I safety :phase1, 2027, 2028
Phase II efficacy :phase2, 2028, 2030
H₂S donors show particular promise in combination approaches:
- With dopaminergic drugs: May reduce L-DOPA-induced dyskinesias
- With mitochondrial agents: Synergy with CoQ10, Mitochondrial dynamics modulators
- With antioxidants: Amplified Nrf2 pathway activation with Sulforaphane
- With anti-inflammatory: Enhanced neuroinflammation control with NLRP3 inhibitors
¶ Challenges and Future Directions
- BBB penetration: Many H₂S donors have limited CNS exposure
- Dosing optimization: Balancing efficacy with H₂S toxicity at high concentrations
- Targeted delivery: Mitochondrial targeting (like AP39) may be superior
- Sustained release: GYY4137 shows promise; newer donors in development
- Biomarker development: Need markers to track H₂S activity in brain
- Caged H₂S donors: Light-activated release for spatial control
- H₂S-NO hybrids: Dual gasotransmitter donors
- CBS activators: Upregulate endogenous H₂S production
- DMSA analogs: Sulfane sulfur donors with different mechanisms